Opioids Can't Stop Califf Confirmation
This article was originally published in The Pink Sheet Daily
Commissioner nominee draws overwhelming Senate support – but also bipartisan opposition to FDA's policy on pain products.
You may also be interested in...
Final Senate vote on Robert Califf’s nomination to lead the US Food and Drug Administration is expected 15 February after Califf narrowly squeaked through a procedural vote. The final vote is expected to be even tighter.
Advisory committees will discuss whether data from a 41-patient study should be added to Pediatric Use section of labeling for Purdue's buprenorphine product; agency's decision to convene expert panel even though a pediatric indication is not being considered grew out of criticism generated by approval of OxyContin for adolescents.
US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.